Mirum Pharma rises on expanded approval for liver disease drug

Mirum Pharmaceuticals

14/03/2024 10:46

** Shares of Mirum Pharmaceuticals  MIRM.O  up 9.1% at
$30.30 premarket 
    ** U.S. health regulator approved late on Wednesday expanded
use of company's oral drug, Livmarli, to treat itching caused by
progressive familial intrahepatic cholestasis (PFIC) 
    ** PFIC is a genetic disorder that causes progressive liver
disease typically leading to organ failure
    ** Livmarli was initially approved in September 2021 to
treat itching caused by another type of genetic liver disorder
known as Alagille Syndrome (ALGS) 
    ** As of last close, stock down ~6% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))